Serum eosinophil cationic protein in children with atopic dermatitis

S Murat-Susić1, J Lipozencić, V Zizić

  • 1Department of Dermatovenerology, Zagreb University Hospital Center, Children's Hospital, Zagreb, Croatia. slosusic@vef.hr

Insights

Children with atopic dermatitis (AD) show elevated eosinophil cationic protein (ECP), eosinophil counts, and IgE antibodies. However, these markers do not correlate with AD severity, suggesting their use as supplementary evaluation tools.

Area of Science:

  • Pediatric Allergy and Immunology
  • Dermatology
  • Clinical Laboratory Science

Background:

  • Eosinophil cationic protein (ECP) is a key mediator released by eosinophils during allergic inflammation.
  • Atopic dermatitis (AD) is a common inflammatory skin condition characterized by elevated eosinophil activity.
  • Understanding biomarkers associated with AD severity is crucial for effective patient management.

Purpose of the Study:

  • To compare ECP levels, eosinophil counts, and IgE antibodies in children with AD versus non-atopic children.
  • To investigate the correlation between these laboratory parameters and the clinical severity of AD, as measured by the SCORAD index.

Main Methods:

  • A prospective study involving 70 children (49 with AD, 21 controls).
  • Measurements included serum ECP, absolute and relative eosinophil counts, and total serum IgE.
  • Clinical severity of AD was assessed using the SCORAD index.

Main Results:

  • Children with AD exhibited significantly higher median levels of IgE antibodies, and absolute and relative eosinophil counts compared to controls (P < 0.001).
  • Serum ECP levels were also significantly higher in children with AD (median 16.2 microg/L) than in controls (median 5.92 microg/L).
  • No statistically significant correlation was found between ECP levels and the SCORAD index or its components (intensity, extent, subjective symptoms).

Conclusions:

  • Elevated ECP, eosinophil counts, and IgE antibodies are characteristic of AD in children.
  • These laboratory findings did not correlate with the clinical severity of AD.
  • ECP, eosinophil counts, and IgE may serve as additional, but not primary, evaluation methods for AD patients.
Abstract

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...